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Hepatitis C virus infection remains a significant global
health problem with more than 130 Million individuals
being chronically infected world-wide. Since 2001, the
standard therapy of chronic hepatitis has been PEG-
IFNa + ribavirin. A large number of new direct acting
antiviral agents is currently explored in clinical trials.
Different viral proteins are targeted by these novel
agents. The first HCV protease inhibitors telaprevir and
boceprevir are expected to be approved in 2011 as
phase III trials have been completed in summer 2010.
At this stage, Direct Acting Anti-Viral agents will only
be used in combination with PEG-IFNa and ribavirin.
Triple therapy will increase sustained virological
response rates by 25-30% for treatment naïve patients
infected with HCV genotype 1 to 70-80% and previous
nonresponder patients may now have chance of 30-50%
to cure the infection. Moreover, treatment will be
“response guided” meaning that patients who are already
HCV RNA negative by week 4 can be treated shorter for
only 24-28 weeks while slow responder still have to
treated for 48 weeks. Resistance will be a problem for
first generation HCV protease inhibitors, in particular if
only suboptimal doses of PEG-IFNa and ribavirin can be
administered. Finally, the new drugs will add additional
side effects as telaprevir may cause rashes in 5-10% of
patients and boceprevir can induce nausea. Both drugs
can induce anaemia which may be more pronounced for
boceprevir.
Additional drugs including “second wave protease
inhibitors”, nucleosidic and non-nucleosidic polymerase
inhibitors, NS5A inhibitors as well as cyclophilin inhibi-
tors are currently explored in phase II studies. All oral
therapies without PEG-IFNa are also explored by differ-
ent companies. In addition therapeutic vaccine trials
aiming to induce immune control are also still ongoing.
It is very likely that the entire treatment concept for
HCV infection will completely change within the next 5
years. Additional challenges will not only include man-
agement of viral resistance but also management of new
side effects which may become of particular importance
in patients with advanced liver disease.
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